Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RGT-419B |
Synonyms | |
Therapy Description |
RGT-419B is a third generation CDK inhibitor with activity against CDK2, CDK4, and CDK6, which potentially inhibits proliferation of tumor cells and tumor growth (Cancer Res 2021;81(4 Suppl):Abstract nr PS16-22). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RGT-419B | RGT419B|RGT 419B | CDK2 Inhibitor 31 CDK4 Inhibitor 17 CDK6 Inhibitor 6 | RGT-419B is a third generation CDK inhibitor with activity against CDK2, CDK4, and CDK6, which potentially inhibits proliferation of tumor cells and tumor growth (Cancer Res 2021;81(4 Suppl):Abstract nr PS16-22). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05304962 | Phase I | RGT-419B | FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer | Recruiting | USA | 0 |